Immune Response News and Research

RSS

Vaccine blocks cocaine high in mice - human trials likely

Researchers have produced a lasting anti-cocaine immunity in mice by giving them a safe vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

4 Jan 2011

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases.

29 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Emergent BioSolutions today announced the initiation of a Phase I clinical trial for NuThraxTM, also known as AV7909, with the dosing of the first subject.

27 Dec 2010

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.

23 Dec 2010

Researchers identify new regulator that play a critical role in B cell development

A team at the Institut de recherches cliniques de Montr-al led by Dr. Tarik M-r-y, President and Scientific Director of the institute and Director of the Hematopoiesis and Cancer research unit, will be publishing an important breakthrough in tomorrow's issue of Immunity, a scientific journal from the Cell Press group. The researchers identified a new regulator playing a critical role in the development B cells, which produce antibodies.

23 Dec 2010

Combination of antigen and wax nanoparticles improves immunogenicity

Particle Sciences, a leading pharmaceutical CRO has formulated a series of wax nanoparticles that, when coupled with an antigen, enhanced its immunogenicity, increasing both systemic and the mucosal immune response.

23 Dec 2010

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

A study in this week's PLoS Medicine suggests that AIDS patients with cryptococcal meningitis who start HIV therapy are predisposed to immune reconstitution inflammatory syndrome - an exaggerated inflammatory immune response that kills up to one-third of affected people - if they have biomarkers in their blood showing evidence of a damaged immune system that is not capable of clearing the fungal infection.

22 Dec 2010

Study provides evidence on prevalence of two separate mosquito species which carry malaria parasite

In notable back-to-back papers appearing in the prestigioous journal Science in October, teams of researchers, one led by Nora Besansky, a professor of biological sciences and a member of the Eck Institute for Global Health at the University of Notre Dame, provided evidence that Anopheles gambiae, which is one of the major mosquito carriers of the malaria parasite in Sub-Saharan Africa, is evolving into two separate species with different traits.

21 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

New CPT code for use with T-SPOT.TB test

Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT®) code has been established by the American Medical Association for use with the T-SPOT®.TB test. The new Category I code, 86481, is described as "Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension." This new code will be effective as of January 1, 2011.

21 Dec 2010

Researchers develop new lung imaging technique that causes minimum tissue disruption

Fast-moving objects create blurry images in photography, and the same challenge exists when scientists observe cellular interactions within tissues constantly in motion, such as the breathing lung. In a recent UCSF-led study in mice, researchers developed a method to stabilize living lung tissue for imaging without disrupting the normal function of the organ.

21 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has renewed funding of the Program for Research on Immune Modeling and Experimentation. This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Gen-Probe announces GTI Diagnostics acquisition from Riverside Company

Gen-Probe Incorporated announced today that the Company has acquired GTI Diagnostics, a privately held specialty diagnostics company focused on the transplantation, blood bank and specialty coagulation markets, for $53 million in cash.

17 Dec 2010

Study reveals immune cell provides new therapeutic strategy for SLE

A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus.

16 Dec 2010

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

CMS increases reimbursement rate for Cylex's immune cell function assay by 267%

Cylex Incorporated® today announced that the Centers for Medicare and Medicaid Services (CMS) nearly tripled the reimbursement for ImmuKnow®, the immune cell function assay FDA-cleared for the detection of cell-mediated immune response in populations undergoing immunosuppressive therapy for organ transplant. This significant increase was granted in a time when the overall CMS clinical fee schedule experienced a comprehensive decrease in laboratory reimbursement rates.

15 Dec 2010

Immune Response News and Research

Vaccine blocks cocaine high in mice - human trials likely

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Researchers identify new regulator that play a critical role in B cell development

Combination of antigen and wax nanoparticles improves immunogenicity

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

Study provides evidence on prevalence of two separate mosquito species which carry malaria parasite

New research sheds light on complex regulatory pathways for effective innate immune system

New CPT code for use with T-SPOT.TB test

Researchers develop new lung imaging technique that causes minimum tissue disruption

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

Study: Biomarkers may aid in early diagnosis of breast cancer

Gen-Probe announces GTI Diagnostics acquisition from Riverside Company

Study reveals immune cell provides new therapeutic strategy for SLE

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

CMS increases reimbursement rate for Cylex's immune cell function assay by 267%

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News